Back
Full-text
Journal article

PD-L1 Expression in Mastocytosis.

  • Williams M Department of Pathology, University of Utah, Salt Lake City, UT 84112, USA. margaret.williams@hsc.utah.edu.
  • Lidke DS Department of Pathology and Comprehensive Cancer Center, University of New Mexico, Albuquerque, NM 87102, USA. Dlidke@salud.unm.edu.
  • Hartmann K Division of Allergy, Department of Dermatology, University of Basel, 4031 Basel, Switzerland. karin.hartmann@usb.ch.
  • George TI Department of Pathology, University of Utah, Salt Lake City, UT 84112, USA. tracy.george@path.utah.edu.
  • 2019-05-16
Published in:
  • International journal of molecular sciences. - 2019
PD-1
PD-L1
immune checkpoint
mastocytosis
Animals
B7-H1 Antigen
Biomarkers, Tumor
Humans
Mastocytosis
Programmed Cell Death 1 Ligand 2 Protein
English Programmed death 1 (PD-1), when activated by its ligands PD-L1 and PD-L2, suppresses active immune cells in normal immune regulation to limit autoimmunity and, in tumors, as a mechanism of immune evasion. PD-L1 expression has been described as both a prognostic and predictive marker in many solid and hematologic neoplasms, as targeted therapies against the PD-1/PD-L1 interaction have gained clinical importance. PD-L1 expression has been assessed in a few studies on mastocytosis. We review this literature and the need for further investigation of the tumor-immune interaction in mastocytosis.
Language
  • English
Open access status
gold
Identifiers
Persistent URL
https://sonar.ch/global/documents/54056
Statistics
Document views: 40 File downloads:
  • Full-text: 0